Loading field map
By the early 1990s, the gap between the number of patients awaiting organ transplants and the supply of donor organs had become a public-health crisis. Meanwhile, synthetic implants—from hip joints to vascular grafts—suffered from long-term failure due to poor integration with living tissue, infection, and mechanical fatigue. Tissue engineering emerged from this double bind: rather than replacing a damaged organ with a foreign device, why not grow a living replacement using the patient's own cells? The challenge was that cells alone, when placed into a defect, would wash away or die. They needed a temporary structure to hold them in place, guide their organization, and deliver biochemical signals. That insight defined the first framework.
In 1993, Robert Langer and Joseph Vacanti published a landmark paper in Science that crystallized tissue engineering around a simple conceptual triad: cells, scaffolds, and growth factors. The idea was to seed a biodegradable polymer scaffold with donor or patient-derived cells, add signaling molecules to direct differentiation and proliferation, and implant the construct into the body. Over time, the scaffold would degrade, leaving behind a fully integrated piece of living tissue. This framework dominated the field for more than a decade and produced early successes, including skin substitutes and cartilage patches. Yet its limitations became increasingly apparent. The synthetic scaffolds did not replicate the complex biochemical and mechanical cues of native extracellular matrix. Immune rejection of both scaffold degradation products and allogeneic cells remained a barrier. And large constructs failed because cells in the interior died from lack of oxygen and nutrients before blood vessels could grow in. Classical tissue engineering had shown that the triad could work for thin, avascular tissues, but it could not scale to solid organs.
One response to the scaffold problem was to remove it entirely. Scaffold-free tissue engineering argued that if cells could be coaxed to produce their own matrix and assemble into sheets or spheroids, the need for a synthetic temporary structure would disappear. Researchers developed techniques such as cell-sheet engineering, where confluent monolayers of cells are detached from culture surfaces as intact sheets and stacked to form thicker tissues. The framework narrowed the field's focus to applications where thin, layered constructs could work—corneal patches, cardiac muscle sheets, and vascular grafts. But scaffold-free approaches hit their own limits: without a scaffold, diffusion alone could not support constructs thicker than about 100–200 micrometers, and the mechanical strength of cell-only constructs was poor. By the mid-2010s, scaffold-free engineering had settled into a specialized niche rather than replacing the classical triad. It coexists with scaffold-based methods, offering an alternative for applications where matrix mimicry matters more than bulk mechanical support.
A different answer to the scaffold problem came from decellularized extracellular matrix (dECM) engineering. Instead of building a scaffold from scratch, this framework strips cells from donated or cadaveric tissues using detergents and enzymes, leaving behind the native extracellular matrix with its preserved architecture, ligand composition, and mechanical properties. The resulting acellular scaffold can then be recellularized with the patient's own cells. dECM engineering absorbed the classical triad's logic—cells plus scaffold plus signals—but replaced the synthetic scaffold with a biologically derived one that the body recognizes as native. This approach has been used clinically for heart valves, tracheas, and bladder patches. Its key limitation is that the decellularization process can damage matrix components, and the supply of donor tissue is finite. Nevertheless, dECM engineering has become infrastructure for later frameworks: it provides the matrix templates that in situ and immunomodulatory approaches often rely on, and it remains an active clinical tradition.
Around 2010, advances in inkjet and extrusion printing technologies were adapted to deposit living cells, hydrogels, and growth factors in precise three-dimensional patterns. 3D bioprinting introduced a fundamentally different fabrication logic: instead of casting or molding a scaffold and then seeding cells, the construct is built layer by layer, with cells and matrix deposited simultaneously. This framework gave tissue engineers programmable spatial control over cell placement, porosity, and material gradients. It did not replace the classical triad so much as transform its manufacturing step. Bioprinting coexists with scaffold-free and dECM approaches—it can print cell-only aggregates or incorporate decellularized matrix as a bioink. Its current limits include the resolution of printed capillaries (still too coarse for full organ vascularization) and the mechanical fragility of printed hydrogels. Bioprinting is now the leading fabrication platform for research-scale tissue constructs, but it has not yet solved the vascularization problem that also plagued classical tissue engineering.
While bioprinting builds tissues from the top down, organoid engineering grows them from the bottom up. By embedding pluripotent or adult stem cells in a basement-membrane-like gel and supplying a carefully timed sequence of growth factors, researchers can trigger self-organization into miniature organs—gut, brain, liver, kidney—that recapitulate many aspects of native tissue architecture and function. Organoid engineering challenged the assumption that scaffolds and external patterning were necessary for complex tissue formation. Its strength is in modeling development and disease rather than producing implantable constructs: organoids lack vascularization and cannot yet be scaled to clinically relevant sizes. The framework has converged with bioprinting in recent years, as researchers print organoids into larger constructs to combine self-organization with spatial control. Organoid engineering remains a living tradition focused on drug screening, disease modeling, and developmental biology, while its clinical-transplantation gap is increasingly addressed by in situ approaches.
Classical tissue engineering treated the immune system as an obstacle to be minimized—use immunoisolation, avoid allogeneic cells, choose bioinert materials. Immunomodulatory tissue engineering reframed the immune response as a resource. Instead of hiding from macrophages and T cells, this framework designs scaffolds and delivery systems that actively steer the immune environment toward regeneration. Strategies include releasing cytokines that recruit anti-inflammatory (M2) macrophages, presenting ligands that promote regulatory T-cell activation, and using biomaterials that degrade into immunomodulatory byproducts. This framework does not stand alone; it cross-cuts nearly every other framework. Decellularized ECM scaffolds are now evaluated for their intrinsic immunomodulatory properties. Bioprinted constructs incorporate immune-signaling gradients. In situ approaches rely on host immune cells to clear debris and guide regeneration. Immunomodulatory tissue engineering has transformed the field's assumptions: the goal is no longer immune evasion but immune collaboration.
The most recent framework, in situ tissue engineering, pushes the logic of immunomodulation and decellularized ECM to its extreme. Instead of building a construct in the lab and implanting it, in situ engineering implants a cell-free scaffold—often a decellularized matrix or a synthetic material loaded with chemoattractants—that recruits the patient's own cells to the defect site and instructs them to regenerate the tissue. This framework eliminates the costly and regulatory-complex step of ex vivo cell expansion. It synthesizes insights from dECM engineering (the scaffold provides native cues) and immunomodulatory engineering (the scaffold's degradation products and surface chemistry steer the host response). In situ approaches have shown promise for bone, cartilage, and vascular regeneration in animal models. Their main limitation is that they rely on the host's endogenous cell supply, which may be depleted or dysfunctional in older or diseased patients. In situ tissue engineering is currently the most ambitious attempt to simplify the clinical pathway while preserving the regenerative logic of the original triad.
The seven frameworks are not a linear succession; most remain active, and their current division of labor reveals both convergence and persistent disagreement. All leading frameworks—bioprinting, organoid engineering, immunomodulatory engineering, and in situ engineering—agree on two points. First, vascularization is the central unsolved problem: no framework has yet produced a fully vascularized, implantable solid organ. Second, immune management is non-negotiable: every scaffold and fabrication strategy must now account for its immunomodulatory profile. The disagreements run along two axes. On fabrication strategy, bioprinting and organoid engineering represent a top-down versus bottom-up divide: can complex tissue architecture be programmed from above, or must it emerge from cellular self-organization? On cell sourcing, in situ and immunomodulatory frameworks favor host-cell recruitment, while classical and bioprinting approaches still rely on ex vivo cell expansion. These are not settled debates; they are live research programs that continue to reshape the field. Tissue engineering today is a pluralistic discipline in which each framework has found a distinctive niche—and in which the most exciting work happens at their intersections.